Colossal Bioscience’s attempt to de-extinct the dire wolf is a dangerously deceptive publicity stunt
By David Coltman, Carson Mitchell, Liam Alastair Wayde Carter, and Tommy Galfano,
The Conversation
| 05. 12. 2025
Colossal Biosciences, a Texas-based biotech company, made headlines this April after falsely claiming to resurrect the extinct dire wolf. The company presents this as a breakthrough for conservation biology. However, our team of conservation geneticists at the Western University — along with many other academics views it as a dangerous deception.
Colossal’s so-called dire wolf is not a resurrected species. It’s a genetically modified grey wolf. Its creation is a publicity stunt designed to generate profit, with serious consequences.
Jenga approach to conservation
Conservation aims to safeguard ecosystems by preserving the networks of interaction between animals and their environment. Human activity has caused widespread habitat loss, driving extinction rates to levels estimated to be about 1,000 times higher than the natural background rate. We are living through a biodiversity crisis, and conservation remains our only real defence against further declines.
Colossal proposes de-extinction to combat this crisis, using a Jenga-block metaphor to explain their approach. The ecosystem is a Jenga tower, with each species representing a block — and losing a species weakens the structure, pushing it...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...